Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 14825632Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2026 award categories
- Radiology
- Neurosurgery
NIH Funding · FY2025
Linked Award Amount
$2.8M
Full award amounts, FY2025
Award Records
4
Records listing this PI
Award-Linked Rank
#3,757
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2025 award records by amount
NIH award records listing Wen Jiang as a PI. Multi-PI records show the full award amount for context.
- 4R01CA284108-03R01Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy$1.1Maward amount
- 5R01CA291876-02R01Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma$645.9Kaward amount
- 1R01CA305986-01R01Microbial-inspired immune-stimulating antibody-toxin conjugate (ATC) for cancer immunotherapy$616.7Kaward amount
- 5R01NS117828-05R01Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody$435.1Kaward amount
Award organization
Organizations that administered FY2025 awards listing Wen Jiang as a PI.
FY2025 award administered by UT MD Anderson Cancer Center (TX).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardUT MD Anderson Cancer Center
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #7737
- 2025$2M Cumulative Funding
- 2025Entered Top 25% NationallyRanked #3757
- 2025R01 Grant Holder
- 2026$5M Cumulative Funding
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Wen Jiang.